Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies

Carol M Richman, Sally J. DeNardo

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT) is a promising approach for treating metastatic breast cancer. Initial clinical trials using 131I radioimmunoconjugates, and more recent studies employing 90Y, have demonstrated objective, although transient, antitumor effects in heavily pretreated patients with minimal toxicity. Antibodies targeting unique epitopes of epithelial glycoprotein mucin (MUC-1) on breast cancer cell surfaces that have been studied in patients include BrE-3 (murine and humanized) and m170 (murine). Both antibodies react with at least 90% of breast cancers. In these and other RIT trials, myelosuppression has been the dose-limiting toxicity. However, this toxicity has been successfully circumvented with the use of autologous peripheral blood stem cell transplantation, and recent clinical trials have escalated 90Y doses up to 50 mCi/m2. The therapeutic index indicates that using these agents with stem cell support should deliver 9000 to 18 000 rads to metastatic tumors. Development of improved chelates that are readily metabolized in the liver may reduce doses to this organ, projected to be next in line as dose-limiting. Combination therapy will be required to produce durable benefits in metastatic breast cancer. Low dose taxanes are synergistic with RIT in preclinical studies and when administered in the optimal sequence could sensitize tumor cells to the continuous low dose radiation delivered by RIT, without increasing toxicity. The addition of systemically administered tumor targeting radiation therapy using RIT as part of combined modality therapy may enhance the rate of complete response and, in patients with minimal metastatic disease, could lead to curative therapy.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume38
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Radioimmunotherapy
Radiotherapy
Breast Neoplasms
Clinical Trials
Immunoconjugates
Peripheral Blood Stem Cell Transplantation
Taxoids
Combined Modality Therapy
Mucin-1
Neoplasms
Antibodies
Epitopes
Glycoproteins
Stem Cells
Therapeutics
MUC-1 monoclonal antibody
Radiation
Liver

Keywords

  • Breast cancer
  • MUC-1 antibodies
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. / Richman, Carol M; DeNardo, Sally J.

In: Critical Reviews in Oncology/Hematology, Vol. 38, No. 1, 2001, p. 25-35.

Research output: Contribution to journalArticle

@article{aa046ae1d9bf4a769d9996d2c42d5cae,
title = "Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies",
abstract = "Radioimmunotherapy (RIT) is a promising approach for treating metastatic breast cancer. Initial clinical trials using 131I radioimmunoconjugates, and more recent studies employing 90Y, have demonstrated objective, although transient, antitumor effects in heavily pretreated patients with minimal toxicity. Antibodies targeting unique epitopes of epithelial glycoprotein mucin (MUC-1) on breast cancer cell surfaces that have been studied in patients include BrE-3 (murine and humanized) and m170 (murine). Both antibodies react with at least 90{\%} of breast cancers. In these and other RIT trials, myelosuppression has been the dose-limiting toxicity. However, this toxicity has been successfully circumvented with the use of autologous peripheral blood stem cell transplantation, and recent clinical trials have escalated 90Y doses up to 50 mCi/m2. The therapeutic index indicates that using these agents with stem cell support should deliver 9000 to 18 000 rads to metastatic tumors. Development of improved chelates that are readily metabolized in the liver may reduce doses to this organ, projected to be next in line as dose-limiting. Combination therapy will be required to produce durable benefits in metastatic breast cancer. Low dose taxanes are synergistic with RIT in preclinical studies and when administered in the optimal sequence could sensitize tumor cells to the continuous low dose radiation delivered by RIT, without increasing toxicity. The addition of systemically administered tumor targeting radiation therapy using RIT as part of combined modality therapy may enhance the rate of complete response and, in patients with minimal metastatic disease, could lead to curative therapy.",
keywords = "Breast cancer, MUC-1 antibodies, Radioimmunotherapy",
author = "Richman, {Carol M} and DeNardo, {Sally J.}",
year = "2001",
doi = "10.1016/S1040-8428(00)00136-0",
language = "English (US)",
volume = "38",
pages = "25--35",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies

AU - Richman, Carol M

AU - DeNardo, Sally J.

PY - 2001

Y1 - 2001

N2 - Radioimmunotherapy (RIT) is a promising approach for treating metastatic breast cancer. Initial clinical trials using 131I radioimmunoconjugates, and more recent studies employing 90Y, have demonstrated objective, although transient, antitumor effects in heavily pretreated patients with minimal toxicity. Antibodies targeting unique epitopes of epithelial glycoprotein mucin (MUC-1) on breast cancer cell surfaces that have been studied in patients include BrE-3 (murine and humanized) and m170 (murine). Both antibodies react with at least 90% of breast cancers. In these and other RIT trials, myelosuppression has been the dose-limiting toxicity. However, this toxicity has been successfully circumvented with the use of autologous peripheral blood stem cell transplantation, and recent clinical trials have escalated 90Y doses up to 50 mCi/m2. The therapeutic index indicates that using these agents with stem cell support should deliver 9000 to 18 000 rads to metastatic tumors. Development of improved chelates that are readily metabolized in the liver may reduce doses to this organ, projected to be next in line as dose-limiting. Combination therapy will be required to produce durable benefits in metastatic breast cancer. Low dose taxanes are synergistic with RIT in preclinical studies and when administered in the optimal sequence could sensitize tumor cells to the continuous low dose radiation delivered by RIT, without increasing toxicity. The addition of systemically administered tumor targeting radiation therapy using RIT as part of combined modality therapy may enhance the rate of complete response and, in patients with minimal metastatic disease, could lead to curative therapy.

AB - Radioimmunotherapy (RIT) is a promising approach for treating metastatic breast cancer. Initial clinical trials using 131I radioimmunoconjugates, and more recent studies employing 90Y, have demonstrated objective, although transient, antitumor effects in heavily pretreated patients with minimal toxicity. Antibodies targeting unique epitopes of epithelial glycoprotein mucin (MUC-1) on breast cancer cell surfaces that have been studied in patients include BrE-3 (murine and humanized) and m170 (murine). Both antibodies react with at least 90% of breast cancers. In these and other RIT trials, myelosuppression has been the dose-limiting toxicity. However, this toxicity has been successfully circumvented with the use of autologous peripheral blood stem cell transplantation, and recent clinical trials have escalated 90Y doses up to 50 mCi/m2. The therapeutic index indicates that using these agents with stem cell support should deliver 9000 to 18 000 rads to metastatic tumors. Development of improved chelates that are readily metabolized in the liver may reduce doses to this organ, projected to be next in line as dose-limiting. Combination therapy will be required to produce durable benefits in metastatic breast cancer. Low dose taxanes are synergistic with RIT in preclinical studies and when administered in the optimal sequence could sensitize tumor cells to the continuous low dose radiation delivered by RIT, without increasing toxicity. The addition of systemically administered tumor targeting radiation therapy using RIT as part of combined modality therapy may enhance the rate of complete response and, in patients with minimal metastatic disease, could lead to curative therapy.

KW - Breast cancer

KW - MUC-1 antibodies

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0035117356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035117356&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(00)00136-0

DO - 10.1016/S1040-8428(00)00136-0

M3 - Article

C2 - 11255079

AN - SCOPUS:0035117356

VL - 38

SP - 25

EP - 35

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -